Renaissance Technologies’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Renaissance Technologies’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-582,632	Closed	-$2.22M	–	3846
2019 Q3	$2.22M	Buy	582,632 +338,700	+139%	+$1.22M	﹤0.01%	2227
2019 Q2	$1.62M	Buy	243,932 +116,038	+91%	+$442K	﹤0.01%	2443
2019 Q1	$454K	Sell	127,894 -64,004	-33%	-$347K	﹤0.01%	2958
2018 Q4	$761K	Buy	+191,898	New	+$2.45M	﹤0.01%	2702
2018 Q3	–	Sell	-21,798	Closed	-$692K	–	3662
2018 Q2	$692K	Sell	21,798 -1,739	-7%	-$62.6K	﹤0.01%	2736
2018 Q1	$871K	Buy	23,537 +7,073	+43%	+$465K	﹤0.01%	2707
2017 Q4	$1.3M	Buy	+16,464	New	+$1.22M	﹤0.01%	2561

Other funds holding MLNT

Stifel Financial St. Louis, Missouri $121B AUM 21.47% 1-Year Est. Return

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Condor Capital Management Martinsville, New Jersey $1.34B AUM 13.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.8M AUM 57.47% 1-Year Est. Return

Renaissance Technologies's MLNT Position: Q4 2019 in Review

Renaissance Technologies sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 582,632 shares — an estimated $2.22M sold.

Renaissance Technologies first reported a position in MLNT in Q4 2017 and held it in 7 quarters. The position peaked at $2.22M in Q3 2019. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

Renaissance Technologies reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Renaissance Technologies sold 582,632 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $2.22M.
Renaissance Technologies first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
Renaissance Technologies's Melinta Therapeutics, Inc. Common Stock position peaked at $2.22M in Q3 2019.
37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.